ESR1 and breast cancer: To observe the effects of HSP90 inhibition on ERα, we treated MCF-7 breast cancer cells with 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), a widely utilized and well characterized HSP90 inhibitor19.